37612-13-8 Usage
Description
Encainide, also known by its brand name Enkaid, is a pharmaceutical compound primarily used as an anti-arrhythmic agent. It belongs to the class of drugs known as encainide-type antiarrhythmics, which are designed to regulate and stabilize the electrical activity of the heart. Encainide is particularly effective in treating serious ventricular tachycardia and is also used for atrial arrhythmia.
Uses
Used in Pharmaceutical Industry:
Encainide is used as a cardiac depressant for the treatment of serious ventricular tachycardia. It helps in stabilizing the electrical activity of the heart, preventing life-threatening arrhythmias and improving the overall cardiac function.
Additionally, Encainide is used as an anti-arrhythmic agent for atrial arrhythmia. It is effective in treating natural occurrences of atrial arrhythmia, providing relief and improving the quality of life for patients suffering from this condition.
Encainide is also used in clinical settings where its effectiveness in treating serious ventricular tachycardia is particularly beneficial. It is prescribed to patients who are at high risk of developing life-threatening arrhythmias, helping to reduce the risk of sudden cardiac events and improving their overall cardiac health.
World Health Organization (WHO)
The membrane-stabilizing antiarrhythmic agent encainide was
introduced into medicine in the mid-1980's. The decision to delete the indications
for patients with asymptomatic and less severe symptomatic ventricular
arrhythmias was taken on the basis of the results of a trial (CAST study) that
showed a two-fold increase in deaths in post-myocardiac patients taking encainide
compared with the placebo group. (See also WHO comment for flecainide).
Synthesis
Encainide, 4-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]-benzamide
(18.1.15), is synthesized by acylating 2-(1-methyl-2-piperidylethyl)aniline with 4-
methoxybenzoic acid chloride. The chemical structure of encainide is substantially
different than other local anesthetics and antiarrhythmics.
Check Digit Verification of cas no
The CAS Registry Mumber 37612-13-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,7,6,1 and 2 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 37612-13:
(7*3)+(6*7)+(5*6)+(4*1)+(3*2)+(2*1)+(1*3)=108
108 % 10 = 8
So 37612-13-8 is a valid CAS Registry Number.
InChI:InChI=1/C22H28N2O2/c1-17-5-3-4-15-24(17)16-14-18-6-10-20(11-7-18)23-22(25)19-8-12-21(26-2)13-9-19/h6-13,17H,3-5,14-16H2,1-2H3,(H,23,25)
37612-13-8Relevant articles and documents
Decarboxylative Anti-Michael Addition to Olefins Mediated by Photoredox Catalysis
Lovett, Gabrielle H.,Sparling, Brian A.
supporting information, p. 3494 - 3497 (2016/07/23)
Decarboxylative coupling of carboxylic acids with activated olefins has been accomplished using visible light photoredox catalysis. The strategic placement of a radical-stabilizing aromatic group at the β-position of the olefin component biases the regios
Substituted piperidines
-
, (2008/06/13)
The compounds are of the heterocyclic class of 2-phenethylpiperidines having an amido substituent in the ortho position of the phenethyl moiety. Substituents in the ortho position include formamido, benzamido, cinnamamido, 2-thiophenecarboxamido, alkanesulfonamido and alkanoylamido. They are useful as antiarrhythmic and/or antiserotonin agents. The novel compounds are prepared by reaction of appropriately substituted o-aminophenethylpiperidines and the carbonyl or sulfonyl halides or anhydrides. Typical embodiments of this invention are 4-methoxy-2'-[2-(1-methyl-2-piperidyl)ethyl]benzanilide and 2'-[2-(1-methyl-2-piperidyl)ethyl]cinnamanilide.
